AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(125 sites)
United States
Research Site, Fort Lauderdale, Florida Research Site, Jupiter, Florida Research Site, Evanston, Illinois Research Site, Peoria, Illinois Research Site, Urbana, Illinois Research Site, Towson, Maryland Research Site, Burlington, Massachusetts Research Site, Worcester, Massachusetts Research Site, Minneapolis, Minnesota Research Site, Omaha, Nebraska Research Site, Las Vegas, Nevada Research Site, The Bronx, New York Research Site, Dayton, Ohio Research Site, Sylvania, Ohio Research Site, San Antonio, Texas Research Site, Tyler, Texas Research Site, Fairfax, Virginia Australia
Research Site, Auchenflower Research Site, Campbelltown Research Site, St Leonards Research Site, Waratah NSW Brazil
Research Site, Porto Alegre Research Site, São José do Rio Preto Canada
Research Site, Edmonton, Alberta Research Site, Hamilton, Ontario Research Site, Kingston, Ontario Research Site, Montreal, Quebec Research Site, Montreal, Quebec Chile
Research Site, Port Montt Research Site, Viña del Mar Czechia
Research Site, Nový Jičín France
Research Site, Saint-Herblain Research Site, Saint-Priest-en-Jarez Germany
Research Site, Schwäbisch Hall India
Research Site, Bhubaneswar Research Site, Dhanvantari Nagar Research Site, Shijiazhuang Age range
18 Years and older
Last updated January 2026